LFVN

LifeVantage Corp

Add to Watchlist

Advanced Chart

12.550

-0.17(-1.336%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

12.730

Open

12.640

VWAP

12.48

Vol

92.24K

Mkt Cap

157.98M

Low

12.340

Amount

1.15M

EV/EBITDA(TTM)

8.51

Total Shares

12.70M

137.65M

EV/OCF(TTM)

10.25

P/S(TTM)

0.75

LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs, and AXIO, its nootropic energy drink mix. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, Spain, Ireland, Singapore, and the Philippines.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

57.93M

+18.39%

0.195

+39.29%

59.60M

+26.23%

0.310

+106.67%

61.80M

-8.8%

0.310

+40.91%

Estimates Revision

The market is revising Downward the revenue expectations for LifeVantage Corporation (LFVN) for FY2025, with the revenue forecasts being adjusted by -4.1% over the past three months. During the same period, the stock price has changed by 7.17%.

Revenue Estimates for FY2025

Revise Downward

-4.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.63%

In Past 3 Month

Stock Price

Go Up

+7.17%

In Past 3 Month

1 Analyst Rating

139.04% Upside

Wall Street analysts forecast LFVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFVN is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

139.04% Upside

Current: 12.550

Low

30.00

Averages

30.00

High

30.00

139.04% Upside

Current: 12.550

Low

30.00

Averages

30.00

High

30.00

Craig-Hallum

Alex Fuhrman

Strong Buy

Initiates

$35

2025-01-14

Reason

Craig-Hallum

Alex Fuhrman

Price Target

$35

2025-01-14

Initiates

Strong Buy

Reason

Craig-Hallum analyst Alex Fuhrman initiated coverage of LifeVantage with a Buy rating and $35 price target.

Lake Street

Brooks O'Neil

Strong Buy

Initiates

$26

2024-12-19

Reason

Lake Street

Brooks O'Neil

Price Target

$26

2024-12-19

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for LifeVantage Corp (LFVN.O) is 11.41, compared to its 5-year average forward P/E of 8.56. For a more detailed relative valuation and DCF analysis to assess LifeVantage Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

8.56

Current PE

11.41

Overvalued PE

13.98

Undervalued PE

3.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Overvalued

5Y Average EV/EBITDA

3.94

Current EV/EBITDA

7.55

Overvalued EV/EBITDA

6.63

Undervalued EV/EBITDA

1.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

0.36

Current PS

0.68

Overvalued PS

0.61

Undervalued PS

0.10

Financials

Annual

Quarterly

FY2025Q3

YoY :

+21.13%

58.44M

Total Revenue

FY2025Q3

YoY :

+109.57%

4.05M

Operating Profit

FY2025Q3

YoY :

+109.16%

3.47M

Net Income after Tax

FY2025Q3

YoY :

+100.00%

0.26

EPS - Diluted

FY2025Q3

YoY :

-32.30%

1.90M

Free Cash Flow

FY2025Q3

YoY :

+2.61%

80.98

Gross Profit Margin - %

FY2025Q3

YoY :

+1.70%

5.39

FCF Margin - %

FY2025Q3

YoY :

+72.67%

5.94

Net Margin - %

FY2025Q3

YoY :

+151.97%

30.11

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

36.8K

USD

3-6

Months

0.0

USD

6-9

Months

364.6K

USD

0-12

Months

0.0

USD

Bought

0-3

4.9K

USD

Months

3-6

0.0

USD

Months

6-9

3.6K

USD

Months

0-12

15.5K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

36.8K

USD

3-6

Months

0.0

USD

6-9

Months

364.6K

USD

0-12

Months

0.0

USD

Bought

0-3

4.9K

USD

Months

3-6

0.0

USD

Months

6-9

3.6K

USD

Months

0-12

15.5K

USD

Months

LFVN News & Events

Events Timeline

2025-07-24 (ET)

2025-07-24

08:16:22

LifeVantage announces upcoming launch into Iceland expected in September

2025-07-22 (ET)

2025-07-22

08:06:12

LifeVantage announces new results from second human study on GLP-1 System

2025-03-17 (ET)

2025-03-17

08:08:23

LifeVantage expands global reach with international launch of MB System

News

9.0

07-22Newsfilter

LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡

5.0

07-04NASDAQ.COM

Insider Sale: Chief Financial Officer of $LFVN Sells 2,746 Shares

4.5

05-30SeekingAlpha

Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave

People Also Watch

TTSH

Tile Shop Holdings Inc

ChoiceOne Financial Services Inc

Ponce Financial Group Inc

Orion Group Holdings Inc

Taysha Gene Therapies Inc

FAQ

What is LifeVantage Corp (LFVN) stock price today?

The current price of LFVN is 12.55 USD — it has decreased -1.34 % in the last trading day.

LFVN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

LFVN News & Events

Events Timeline

News

People Also Watch

FAQ

What is LifeVantage Corp (LFVN) stock price today?

What is LifeVantage Corp (LFVN)'s business?

What is the price predicton of LFVN Stock?

What is LifeVantage Corp (LFVN)'s revenue for the last quarter?

What is LifeVantage Corp (LFVN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for LifeVantage Corp (LFVN)'s fundamentals?

How many employees does LifeVantage Corp (LFVN). have?

What is LifeVantage Corp (LFVN) market cap?